FCE 27733

Drug Profile

FCE 27733

Latest Information Update: 30 May 2001

Price : $50

At a glance

  • Originator Pharmacia Corporation
  • Class Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Anxiety disorders; Nausea and vomiting; Psychotic disorders

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 05 Feb 1997 No-Development-Reported for Emesis in Italy (Unknown route)
  • 05 Feb 1997 No-Development-Reported for Psychotic disorders in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top